News & Events
Published On: 5/7/2020
Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
DURHAM, N.C., May 7, 2020 /PRNewswire/ -- TARGET PharmaSolutions, an innovative healthcare data company that generates real-world clinical data and evidence, announced today the latest research findings from its inflammatory bowel disease study (TARGET-IBD), which was published in the May issue of the peer-reviewed journal Gastroenterology.
The abstract, "Objective Disease Activity Assessment and Therapeutic Drug Monitoring (TDM) is Lacking Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD," was accepted to the annual Digestive Disease Week conference, originally planned to take place in Chicago.
The research aimed to describe the objective marker and therapeutic drug monitoring assessments used in routine clinical practice, prior to biologic therapeutic changes due to loss of response in adult participants. More than 30% of both Crohn's disease and ulcerative colitis patients lacked any type of assessment in the 12 weeks leading up to dose changes; for dose discontinuations, this value was over 20%.
"This analysis brought to light that objective monitoring prior to changes in therapeutics is lacking in many cases," said first author Benjamin Click, MD, staff gastroenterologist at Cleveland Clinic. "Improved understanding of reasons for failure may optimize biologic positioning and outcomes in IBD."
TARGET-IBD is a prospective longitudinal cohort of over 4,000 IBD patients receiving usual care from 34 academic and community centers throughout the U.S. Data is collected retrospectively for three years from the patient's date of consent and then prospectively for at least five years. The resultant robust cohort allows for the collection of effectiveness and safety data upon new drug approvals.
An additional abstract was submitted by TARGET PharmaSolutions for its nonalcoholic steatohepatitis (NASH) study, TARGET-NASH, and was also accepted for publication. Gastroenterology is the official journal of the American Gastroenterological Association Institute.
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
984.234.0268 ext 205
12/04/2023Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient Care
11/13/2023Real-World Evidence in Pharmaceutical Drug Development – Faster, Safer and More Relevant?
10/23/2023Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient Population
11/13/2023TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment Options
11/10/2023Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver Diseases